Acute Kidney Injury after Bone Marrow Transplantation in Patients with Lymphomas and Leukemias

• Autor(a) principal: Mota, Anna Carolina Macieira Feitosa
• Data de Publicação: 2023
• Outros Autores: Alves, Joubert Araújo, Canicoba, Gabriel Stecca, Brito, Germana Alves de, Vieira, Garles Miller Matias, Baptista, Aline Lourenço, Andrade, Luis André Silvestre, Imanishe, Marina Harume, Pereira, Benedito Jorge
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3423
• topic: leukemia; lymphoma; bone marrow transplantation; acute kidney injury; leucemia; linfoma; transplante de medula óssea; injúria renal aguda; leucemia; linfoma; trasplante de médula ósea; lesión renal aguda

Introduction: Hematologic malignancies, including lymphomas and leukemias, may be treated with autologous or allogeneic bone marrow transplantation. However, these approaches can increase the risk of infection, sepsis, graft-versus-host disease, and nephrotoxicity, possibly resulting in acute kidney injury (AKI). Objective: To evaluate AKI in patients with lymphomas or leukemia submitted to bone marrow transplantation (BMT). Method: Retrospective, observational cohort study of cases from a database of 256 patients (53.9% males) hospitalized for BMT between 2012 and 2014 at a cancer hospital in Sao Paulo, Brazil. Of these, 79 were selected randomly for analysis. Demographic data, length of hospitalization, and associated morbidities were recorded. AKI was identified according to Kidney Diseases Improving Global Outcomes (KDIGO) criteria. Results: The most frequent diagnoses for the 79 cases were non-Hodgkin’s lymphoma (30.4%), acute myeloid leukemia (26.6%), and Hodgkin’s lymphoma (24.1%). The probability of 100 days-survival after BMT was 81%, and three years after BMT was 61%. In-hospital mortality was significantly higher among patients who presented AKI during hospitalization (p<0.001). However, there was no difference in overall life expectancy (p=0.770). Conclusion: A significant prevalence of AKI was found in patients with leukemia or lymphoma while they were hospitalized for BMT, resulting in significantly increased rates of in-hospital mortality. The presence of AKI during hospitalization was not associated with a subsequent reduction in life expectancy.